The Gamma Knife
We are the leader in Gamma Knife unit ownership with approximately a 16% market share in the United States.


The Leksell Gamma Knife is the worldwide radiosurgical leader in non-invasive treatment of malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia (facial pain). Patients who undergo Gamma Knife treatment have comparable or better outcomes, fewer complications, faster recoveries, and shorter hospital stays compared to those who undergo an open neurosurgical procedure for certain indications. Worldwide, more than 500,000 patients have received Gamma Knife treatment. Additionally, the Gamma Knife has an impressive scientific track record with thousands of peer-reviewed articles – no other non-invasive treatment method in this field has greater clinical acceptance.